Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.

Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, Tahir A, Igreja SC, Chapple JP, Jordan S, Lupp A, Schulz S, Ansorge O and 5 more

Show all authors

Karavitaki N, Carlsen E, Wass JA, Grossman AB, Korbonits M

The Journal of clinical endocrinology and metabolism1 Jun 2012Cited by 101 (Europe PMC)

PMID22659247DOI10.1210/jc.2012-1111PepBankPUB-22659247

Source link PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In acromegaly patients, lanreotide pretreatment reduced GH (P<0.0001).
In plain wordsIn acromegaly patients, lanreotide pretreatment reduced growth hormone.
Peptide
Lanreotide
Outcome
DecreaseGH
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
P value
< 0.0001 P
GH, lanreotide pretreatment
Source sentences
Summary
Lanreotide pretreatment reduced GH and IGF-I levels and tumor volume (all P < 0.0001).
3 context sentences(design, population, supporting numbers)
Summary · context
In the human study, a 16-wk somatostatin analog pretreatment compared with no pretreatment.
Summary · context
Thirty-nine sporadic and 10 familial acromegaly patients participated in the study.
Summary · context
Interventions included preoperative lanreotide treatment and pituitary surgery.
Report a problemFND-2265924701
02HumanNon-randomized trialEfficacy outcome
In acromegaly patients, lanreotide pretreatment reduced IGF-I (P<0.0001).
In plain wordsIn acromegaly patients, lanreotide pretreatment reduced IGF-I.
Peptide
Lanreotide
Outcome
DecreaseIGF-I
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
P value
< 0.0001 P
IGF-I, lanreotide pretreatment
Source sentences
Summary
Lanreotide pretreatment reduced GH and IGF-I levels and tumor volume (all P < 0.0001).
3 context sentences(design, population, supporting numbers)
Summary · context
In the human study, a 16-wk somatostatin analog pretreatment compared with no pretreatment.
Summary · context
Thirty-nine sporadic and 10 familial acromegaly patients participated in the study.
Summary · context
Interventions included preoperative lanreotide treatment and pituitary surgery.
Report a problemFND-2265924702
03HumanNon-randomized trialEfficacy outcome
In acromegaly patients, lanreotide pretreatment reduced tumor volume (P<0.0001).
In plain wordsIn acromegaly patients, lanreotide pretreatment reduced tumor volume.
Peptide
Lanreotide
Outcome
DecreaseTumor volume
Study
n: not reported in source
Outcome group
Tumor growth · Endocrine and hormones
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
P value
< 0.0001 P
tumor volume, lanreotide pretreatment
Source sentences
Summary
Lanreotide pretreatment reduced GH and IGF-I levels and tumor volume (all P < 0.0001).
3 context sentences(design, population, supporting numbers)
Summary · context
In the human study, a 16-wk somatostatin analog pretreatment compared with no pretreatment.
Summary · context
Thirty-nine sporadic and 10 familial acromegaly patients participated in the study.
Summary · context
Interventions included preoperative lanreotide treatment and pituitary surgery.
Report a problemFND-2265924703
04HumanNon-randomized trialMechanism
In acromegaly patients, AIP immunostaining was stronger after lanreotide pretreatment than with surgery only (P<0.001).
In plain wordsIn acromegaly patients, AIP staining was stronger after lanreotide pretreatment than with surgery only.
Peptide
Lanreotide
Outcome
IncreaseAIP immunostaining
Study
n: not reported in source
Comparator
Surgery only
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
P value
< 0.001 P
AIP immunostaining, lanreotide-pretreated versus surgery-only
Source sentences
Summary
AIP immunostaining was stronger in the lanreotide-pretreated group vs. the surgery-only group (P < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
In the human study, a 16-wk somatostatin analog pretreatment compared with no pretreatment.
Summary · context
Thirty-nine sporadic and 10 familial acromegaly patients participated in the study.
Summary · context
Interventions included preoperative lanreotide treatment and pituitary surgery.
Report a problemFND-2265924704
05HumanObservational studyMechanism
In female acromegaly patients after lanreotide pretreatment, AIP score correlated with IGF-I changes (R=0.68, P<0.05).
In plain wordsIn female acromegaly patients after lanreotide pretreatment, AIP score was linked to IGF-I changes.
Peptide
Lanreotide
Outcome
Not applicableAIP score and IGF-I change correlation
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
Correlation coefficient between AIP score and IGF-I change
0.68 R
females after lanreotide pretreatment
P value
< 0.05 P
females after lanreotide pretreatment
Source sentences
Summary
After lanreotide pretreatment, the AIP score correlated to IGF-I changes in females (R = 0.68, P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
In the human study, a 16-wk somatostatin analog pretreatment compared with no pretreatment.
Summary · context
Thirty-nine sporadic and 10 familial acromegaly patients participated in the study.
Summary · context
Interventions included preoperative lanreotide treatment and pituitary surgery.
Report a problemFND-2265924705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.